Vir Biotechnology, Inc. (VIR)

28.60 +0.75 (+2.69%) At close: 04:00PM EDT

Vir Biotechnology, Inc.

499 Illinois Street
Suite 500
San Francisco, CA 94158
United States
415 906 4324
https://www.vir.bio

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 444

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. George A. Scangos Ph.D.	Pres, CEO & Director	1.07M	N/A	1948
Mr. Howard Horn	Exec. VP, CFO & Sec.	732.41k	N/A	1978
Dr. Ann M. Hanly Ph.D.	Exec. VP & Chief Technology Officer	922.22k	N/A	1970
Dr. Herbert W. Virgin IV, M.D., Ph.D.	Exec. VP of Research & Chief Scientific Officer	1.12M	9.49M	1956
Dr. Phillip Pang M.D., Ph.D.	Exec. VP & Chief Medical Officer	780.46k	3.66M	1975
Dr. Klaus Frueh Ph.D.	Co-Founder & Scientific Advisor	N/A	N/A	1960
Dr. Lawrence Corey	Co-Founder & Scientific Advisor	N/A	N/A	N/A
Dr. Louis J. Picker M.D.	Co-Founder & Scientific Advisor	N/A	N/A	N/A
Ms. Johanna Friedl-Naderer	Exec. VP & COO	N/A	N/A	1968
Mr. Steven J. Rice	Exec. VP & Chief Admin. Officer	N/A	N/A	1960

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Corporate Governance

Vir Biotechnology, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.